Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide

NCT03139851 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT03139851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03139851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Completed
Start date
June 27, 2017
Completion date
September 18, 2019
Enrollment
36 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer